

**Response Under 37 CFR 1.116**

**Expedited Procedure**

**Examining Group 1600**

Application No. 09,743,781

Paper Dated: September 28, 2004

In Reply to USPTO Correspondence of June 1, 2004

Attorney Docket No. 4303-030806

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims**

*Do not enter claim*

1. (Currently Amended): A method of modifying beta-amyloid-induced vasoactivity in individuals with Alzheimer's Disease or related disorders, and other vascular-related diseases or disorders, such as cerebral amyloid angiopathy, vascular amyloidosis, hypertension or vasospasm associated with severe post-traumatic head injury comprising antagonizing the phospholipase A2/arachidonic acid/5-lipoxygenase/cyclo-oxygenase-2 pro-inflammatory pathway by administering a pharmaceutically effective amount of a phospholipase A2 inhibitor to the individual in an amount ranging from between about 0.1 ng to 10 mg/kg body weight/day.

2. (Previously Presented): The method according to claim 1, further defined as upregulating the soluble A $\beta$  pro-inflammatory pathway.

3. (Currently Amended): The method according to claim 1, further defined as down-regulating the soluble A $\beta$  pro-inflammatory pathway.

4-21. (Canceled)